Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

736.64 -15.98 (-2.12%)
Streaming Delayed Price Updated: 1:18 PM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

Regeneron Says FDA Will Take More Time to Review Its Two Eylea HD Submissions ↗
Via Stocktwits
News headline image
EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 of Wall Street’s Favorite Stocks with Open Questions
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
News headline image
Immuno-Oncology Stocks Q2 In Review: Incyte (NASDAQ:INCY) Vs Peers
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Incyte (NASDAQ:INCY) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
These S&P500 stocks are moving in today's session ↗
Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
News headline image
REGN Q2 Deep Dive: New Indications and Pipeline Progress Offset EYLEA Challenges
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% year on year to $3.68 billion. Its non-GAAP profit of $12.89 per share was... 
Via StockStory
News headline image
Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed... 
Via StockStory
Topics Bonds Economy Lawsuit
News headline image
This Stock Has Tumbled 50% In One Year, Gets A Price Target Cut Today – But Retail Believes $400-450 Is A Good Entry Point ↗
Truist, however, kept a ‘Buy’ rating on the shares. 
Via Stocktwits
News headline image
A Look Into Regeneron Pharmaceuticals Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
How Do Investors Really Feel About Regeneron Pharmaceuticals? ↗
 
Via Benzinga
News headline image
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
These Analysts Increase Their Forecasts On Regeneron Pharmaceuticals After Better-Than-Expected Earnings ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 15 Analysts Discuss Regeneron Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
Is Regeneron Pharmaceuticals Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts ↗
These biotech businesses look compelling for very different reasons. 
Via The Motley Fool
News headline image
Regeneron (REGN) Q2 EPS Jumps 53% ↗
Via The Motley Fool
News headline image
Why Regeneron (REGN) Stock Is Trading Up Today
Shares of biotech company Regeneron (NASDAQ:REGN) jumped 3.3% in the morning session after the company reported strong second-quarter financial results that significantly surpassed analyst... 
Via StockStory
Topics Artificial Intelligence
News headline image
Stocks Sell Off, Gold Rallies On Tariff Turmoil, Weak Jobs Data: What's Moving Markets Friday? ↗
It's a rough start to the new month for Wall Street, as major U.S. stock indices plunged by midday Friday, setting the stage for a negative weekly close. 
Via Benzinga
News headline image
4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study ↗
4D Molecular's 4D-150 showed sustained vision and anatomical improvements with fewer injections in DME, supported by regulatory alignment. 
Via Benzinga
News headline image
Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines ↗
Regeneron Q2 revenue rose 4% to $3.68 billion, driven by Dupixent and antibody profits, while FDA delays impacted Eylea HD and odronextamab approvals. 
Via Benzinga
News headline image
Regeneron Pharmaceuticals (NASDAQ:REGN) Beats Q2 2025 Earnings Estimates but Faces Muted Market Reaction ↗
Regeneron Q2 2025 earnings beat estimates with $3.68B revenue and $12.89 EPS, but stock dips in pre-market trading. Dupixent sales surge 22% to $4.34B. 
Via Chartmill
Topics Earnings
News headline image
Regeneron’s (NASDAQ:REGN) Q2: Strong Sales
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% year on year to $3.68 billion. Its non-GAAP profit of $12.89 per share was... 
Via StockStory
News headline image
Regeneron Reports Second Quarter 2025 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Pharmaceuticals Likely To Report Lower Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 1, 2025 ↗
 
Via Benzinga
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch ↗
Via Stocktwits
Topics Government
News headline image
Exploring Regeneron Pharmaceuticals's Earnings Expectations ↗
 
Via Benzinga
News headline image
Regeneron (REGN) Q2 Earnings: What To Expect
Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings this Friday before market open. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence Government World Trade
News headline image
2 Healthcare Stocks That Are Losing to the S&P 500 This Year ↗
Wall Street might be underestimating these companies' potential. 
Via The Motley Fool
Topics Stocks
News headline image
$1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.